PA-SYNERGIS-SOFTWARE
24.3.2022 13:23:11 CET | Business Wire | Press release
Synergis Software , a global leader in engineering document management and workflow solutions, announced today that Synergis Adept was named as a Leader in the Enterprise Content Management and Product Data Management categories in the G2 Spring 2022 Grid® Reports. G2 is a peer-to-peer business software review website that helps companies choose the best tools for their business. Products in the Leader quadrant are rated highly by verified users of the software product and have significant market presence scores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005238/en/
According to G2’s 2022 Spring Reports, Adept software earned 18 G2 Badges with top placements for “Best Usability”, “Fastest Implementation”, “Ease of Setup”, “Ease of Admin”, and “Highest User Adoption”, and grade the company as “Easiest to do Business With” and “Best Support”—recognition Synergis has received consistently over the past seven quarters.
“These achievements reflect the experience we deliver with our software and the relationships we build with some of the world’s best companies,” says Scott Lamond, vice president of marketing at Synergis Software. “Delivering value in ways that are meaningful to our customers is our top priority, so the G2 results really matter to us. Our customers range from small to very large across varied industries , and they’re all part of the Synergis family. We’re grateful for their trust and inspired to bring them even greater value as we grow together.”
G2 highlights the value of Adept engineering document management software across three categories: Enterprise Content Management, Product Data Management, and Construction Drawing Management. G2 Spring 2022 badges include:
- Leader Enterprise Content Management (ECM)
- Leader Product Data Management (PDM)
- Momentum Leader Enterprise Content Management (ECM)
- Momentum Leader Product Data Management (PDM)
- High Performer Mid-Market Enterprise Content Management (ECM)
- High Performer Mid-Market Product Data Management (PDM)
- High Performer Construction Management
- High Performer Construction Drawing Management
- Best Relationship
- Best Support
- Best Support Small-Business
- Easiest To Do Business With Mid-Market
- Easiest To Do Business With
- Easiest To Do Business With Small-Business
- Fastest Implementation
- Highest User Adoption
- Most Implementable
- Best Usability
The G2 reports are based on direct customer feedback combined with G2’s unique algorithm that calculates customer satisfaction and market presence scores in real-time.
For more details about Adept in the G2 Spring 2022 Reports, visit our website .
Quotes from Verified Users about Synergis Adept
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites."
Teresa Yang, Product Manager, Document Management, Dow Chemical
“No other software company anywhere works as closely with their customers. The staff is incredibly responsive and consistently goes above and beyond to solve customer issues. For a system your business cannot operate without, this is invaluable.”
Ryan Mongeau, Director of Technology, Space Age Electronics
“Adept has improved our efficiency/processes by 200%. What once took hours in the old systems, I can do in minutes. It’s a very powerful system with unlimited possibilities for adding more useful information for future projects. And the Helpdesk team can tackle and/or resolve any issue I bring to them to improve or streamline our processes.”
Milias H, The Folger Company, Document Control Service Provider
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
Adept has been battle tested by engineers for over 30 years with customers such as Dow Chemical, Con Edison, General Mills, Merck, NASA, and Nucor Steel.
About G2 Crowd
G2 is the world’s largest tech marketplace where businesses can discover, review, and manage the technology they need to reach their potential. Today, more than 3M people visit G2 to read and write authentic reviews about thousands of software products and professional services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005238/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom